
Proteome Sciences plc – LSE:PRM.L
Proteome Sciences stock price today
Proteome Sciences stock price monthly change
Proteome Sciences stock price quarterly change
Proteome Sciences stock price yearly change
Proteome Sciences key metrics
Market Cap | 9.88M |
Enterprise value | 1.31B |
P/E | 4.51 |
EV/Sales | 310.06 |
EV/EBITDA | 229407.18 |
Price/Sales | 3.12 |
Price/Book | -5.23 |
PEG ratio | -0.05 |
EPS | 19.39 |
Revenue | 47.23B |
EBITDA | -4.50B |
Income | 9.29B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -5.09% |
Oper. margin | -2.78% |
Gross margin | 63.06% |
EBIT margin | -2.78% |
EBITDA margin | -9.54% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProteome Sciences stock price history
Proteome Sciences stock forecast
Proteome Sciences financial statements
Jun 2022 | 12.86B | 2.47B | 19.24% |
---|---|---|---|
Dec 2022 | 10.87B | 2.54B | 23.43% |
Jun 2023 | 12.62B | 3.11B | 24.64% |
Dec 2023 | 10.87B | 1.16B | 10.7% |
Jun 2022 | 10966000 | 13.51M | 123.2% |
---|---|---|---|
Dec 2022 | 12433000 | 13.27M | 106.78% |
Jun 2023 | 1549714000000 | 471.90B | 30.45% |
Dec 2023 | 1477487000000 | 1.40T | 95.14% |
Jun 2022 | 13.01B | -14.93B | 43.73B |
---|---|---|---|
Dec 2022 | -9.13B | -6.73B | -16.69B |
Jun 2023 | 14.99B | -14.78B | 8.72B |
Dec 2023 | -8.96B | -8.63B | -17.07B |
Proteome Sciences alternative data
Aug 2023 | 27 |
---|---|
Sep 2023 | 27 |
Oct 2023 | 27 |
Nov 2023 | 29 |
Dec 2023 | 29 |
Jan 2024 | 29 |
Feb 2024 | 29 |
Mar 2024 | 29 |
Apr 2024 | 29 |
May 2024 | 35 |
Jun 2024 | 35 |
Jul 2024 | 35 |
Proteome Sciences other data
Insider | Compensation |
---|---|
Dr. Mariola Söhngen (1961) Chief Executive Officer & Executive Director | $251,910 |
Mr. Richard Paul Dennis (1959) Chief Commercial Officer & Executive Director | $184,000 |
-
What's the price of Proteome Sciences stock today?
One share of Proteome Sciences stock can currently be purchased for approximately $5.13.
-
When is Proteome Sciences's next earnings date?
Unfortunately, Proteome Sciences's (PRM.L) next earnings date is currently unknown.
-
Does Proteome Sciences pay dividends?
No, Proteome Sciences does not pay dividends.
-
How much money does Proteome Sciences make?
Proteome Sciences has a market capitalization of 9.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.98% to 5.03M US dollars.
-
What is Proteome Sciences's stock symbol?
Proteome Sciences plc is traded on the LSE under the ticker symbol "PRM.L".
-
What is Proteome Sciences's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Proteome Sciences?
Shares of Proteome Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Proteome Sciences's key executives?
Proteome Sciences's management team includes the following people:
- Dr. Mariola Söhngen Chief Executive Officer & Executive Director(age: 64, pay: $251,910)
- Mr. Richard Paul Dennis Chief Commercial Officer & Executive Director(age: 66, pay: $184,000)
-
How many employees does Proteome Sciences have?
As Jul 2024, Proteome Sciences employs 35 workers, which is 21% more then previous quarter.
-
When Proteome Sciences went public?
Proteome Sciences plc is publicly traded company for more then 29 years since IPO on 3 Oct 1995.
-
What is Proteome Sciences's official website?
The official website for Proteome Sciences is proteomics.com.
-
How can i contact Proteome Sciences?
Proteome Sciences can be reached via phone at +44 20 7043 2116.
Proteome Sciences company profile:

Proteome Sciences plc
proteomics.comLSE
35
Medical - Diagnostics & Research
Healthcare
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Cobham, KT11 3EP
:
ISIN: GB0003104196
CUSIP: G2994J105